Anemia and heart failure

Current Opinion in Cardiology

Volumn 24, Issue 2, 2009, Pages 172-178

  Ghali, Jalal K ^a,b  

^a HARPER UNIVERSITY HOSPITAL   (United States)

^b NONE   (United States)

Author keywords

Anemia; Erythropoietin; Heart failure; Iron

Indexed keywords

ACETYLSALICYLIC ACID; ANGIOTENSIN II; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIANEMIC AGENT; ANTICOAGULANT AGENT; BETA ERYTHROPOIETIN; CYANOCOBALAMIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRIL; ERYTHROPOIETIN; FOLIC ACID; HEMOGLOBIN; IRON; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; PLACEBO; UNCLASSIFIED DRUG; VALSARTAN;

ANEMIA; BLOOD TRANSFUSION; CLINICAL FEATURE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CYANOCOBALAMIN DEFICIENCY; DOSE RESPONSE; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG SAFETY; FOLIC ACID DEFICIENCY; HEART FAILURE; HEART LEFT VENTRICLE EJECTION FRACTION; HEMATOCRIT; HUMAN; INFLAMMATION; IRON DEFICIENCY ANEMIA; KIDNEY DYSFUNCTION; PATHOPHYSIOLOGY; PREVALENCE; PRIORITY JOURNAL; PROGNOSIS; RANDOMIZED CONTROLLED TRIAL; REVIEW; SIDE EFFECT; THROMBOSIS; UNSPECIFIED SIDE EFFECT;

ANEMIA; HEART FAILURE; HEMATINICS; HUMANS; PREVALENCE;

EID: 62249145007     PISSN: 02684705     EISSN: None     Source Type: Journal    
DOI: 10.1097/HCO.0b013e328324ecec     Document Type: Review

References (78)

1. Lang CC, Mancini DM. Noncardiac co morbidities in chronic HF. Heart 2007; 93:665-671.
2. WHO. Iron deficiency anemia assessment, prevention and control: a guide for programmed managers. Geneva, Switzerland: WHO; 2001.
3. National Kidney Foundation. National Kidney Foundation Kidney Disease Outcomes Quality Initiative. Clinical practice guidelines for anemia of chronic kidney disease: 2000 update. Am J Kidney Dis 2001; 37 (Suppl 1):S182-S238.
4. Beutler E, Waalen J. The definition of anemia: what is the lower limit of normal of the blood hemoglobin concentration? Blood 2006; 107:1747-1750.
5. Lindenfeld J. Prevalence of anemia and effects on mortality in patients with HF. Am Heart J 2005; 149:391-401.
6. Young JB, Abraham WT, Albert NM, et al. Relation of low hemoglobin and anemia to morbidity and mortality in patients hospitalized with heart failure (insight from the OPTIMIZE-HF registry). Am J Cardiol 2008; 101:223-230.
7. Kosiborod M, Smith GL, Radford MJ, et al. The prognostic importance of anemia in patients with heart failure. Am J Med 2003; 114:112-119.
8. Dunlay DM, Weston SA, Redfield MM, et al. Anemia and heart failure: a community study. Am J Med 2008; 121:726-732.
9. Cromie N, Lee C, Struthers AD, et al. Anaemia in chronic HF. what is its frequency in the UK and its underlying causes? Heart 2002; 87:377-378.
10. Witte KK, Desilva R, Chattopadhyay S, et al. Are hematinic deficiencies the cause of anemia in chronic HF? Am Heart J 2004; 147:924-930.
11. Bolger AP, Bartlett FR, Penston HS, et al. Intravenous iron alone for the treatment of anemia in patients with chronic heart failure. J Am Coll Cardiol 2006; 48:1225-1227.
12. Opasich C, Cazzola M, Scelsi L, et al. Blunted erythropoietin production and defective iron supply for erythropoiesis as major causes of anemia in patients with chronic heart failure. Eur Heart J 2005; 26:2232-2237.
13. Nanas JN, Matsouka C, Karageorgopoulos D, et al. Etiology of anemia in patients with advanced heart failure. J Am Coll Cardiol 2006; 48:2485-2489.
14. Westenbrink BD, Voors AA, van Veldhuisen DJ. Is anemia in chronic heart failure cased by iron deficiency? J Am Coll Cardiol 2007; 49:2301.
15. Macdougall IC, Cooper AC. Erythropoietin resistance: the role of inflammation and proinflammatory cytokines. Nephrol Dial Transplant 2002; 17 (Suppl 11):39-43.
16. Eschbach JW. Anemia management in chronic kidney disease: role of factors affecting epoetin responsiveness. J Am Soc Nephrol 2002; 61:1412-1414.
17. Weiss G, Goodnough LT. Anemia of chronic disease. N Engl J Med 2005; 352:1011-1023.
18. Mann DL. Activation of inflammatory mediators in heart failure. In: Mann DL, editor. Heart failure. Philadelphia: Saunders; 2004.
19. Ezekowitz JA, McAlister FA, Armstrong PW. Anemia is common in heart failure and is associated with poor outcomes: insights from a cohort of 12,065 patients with new-onset heart failure. Circulation 2003; 107:223-225.
20. Androne AS, Katz SD, Lund L, et al. Hemodilution is common in patients with advanced heart failure. Circulation 2003; 107:226-229.
21. Westenbrink BD, Visser FW, Voors AA, et al. Anaemia in chronic heart failure is not only related to impaired renal perfusion and blunted erythropoietin production, but to fluid retention as well. Eur Heart J 2007; 28:166-171.
22. Adlbrecht C, Kommata S, Hülsmann M, et al. Chronic heart failure leads to an expanded plasma volume and pseudoanaemia, but does not lead to a reduction in the body's red cell volume. Eur Heart J 2008; 19:2343-2350. This study points out the high prevalence and importance of expanded plasma volume in patients with heart failure and anemia.
23. Besarab A, Bolton WK, Browne JK, et al. The effect of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoetin. N Engl J Med 1998; 339:584-590.
24. Phrommintikul A, Haas SJ, Elsik M, Krum H. Mortality and target haemoglobin concentrations in anaemic patients with chronic kidney disease treated with erythropoietin: a meta-analysis. Lancet 2007; 369:381-388.
25. Ishani A, Weinhandl E, Zhao Z, et al. Angiotensin-converting enzyme inhibitor as a risk factor for the development of anemia, and the impact of incident anemia on mortality in patients with left ventricular dysfunction. J Am Coll Cardiol 2005; 45:391-399.
26. Anand IS, Kuskowski MA, Rector TS, et al. Anemia and change in hemoglobin over time related to mortality and morbidity in patients with chronic heart failure: results from Val-HeFT. Circulation 2005; 112:1121-1127.
27. Terrovitis JV, Anastasiou-Nana MI, Alexopoulos GP, et al. Prevalence and prognostic significance of anemia in patients with congestive heart failure treated with standard vs high doses of enalapril. J Heart Lung Transplant 2006; 25:333-338.
28. Jelkmann W. Erythropoietin after a century of research: younger than ever. Eur J Haematol 2007; 78:183-205. This is an excellent summary of erythropoietin biology including its cardioprotective potential.
29. Mrug M, Stopka T, Julian BA, et al. Angiotensin II stimulates proliferation of normal early erythroid progenitors. J Clin Invest 1997; 100:2310-2314.
30. van der Meer P, Lipsic E, Westenbrink BD, et al. Levels of hematopoiesis inhibitor N-acetyt-seryl-aspartyl-lysyl-proline partially explain the occurrence of anemia in heart failure. Circulation 2005; 112:1743-1747.
31. George J, Fatal S, Wexler D, et al. Circulating erythropoietin levels and prognosis in patients with congestive heart failure: comparison with neurohormonal and inammatory markers. Arch Intern Med 2005; 165:1304-1309.
32. van der Meer P, Voors AA, Lipsic E, et al. Prognostic value of plasma erythropoietin on mortality in patients with chronic heart failure. J Am Coll Cardiol 2004; 44:63-67.
33. Jelkmann W. Proinflammatory cytokines lowering erythropoietin production. J Interferon Cytokine Res 1998; 18:555-559.
34. Handelman GJ, Levin NW. Iron and anemia in human biology: a review of mechanisms. Heart Fail Rev 2008; 4:393-404. An excellent review of the biology of iron in anemia.
35. Faraz HA, Zafar SF, Ghali JK. Anemia and the potential role of erythropoiesis-stimulating agents in heart failure. Curr Heart Fail Rep 2008; 5:83-90.
36. Groenveld HF, Januzzi JL, Damman K, et al. Anemia and mortality in heart failure patients a systematic review and meta-analysis. J Am Coll Cardiol 2008; 52:818-827. A meta-analysis of published studies relating anemia in heart failure to mortality.
37. Kalra PR, Collier T, Cowie MR, et al. Haemoglobin concentration and prognosis in new cases of heart failure. Lancet 2003; 362:211-212.
38. Maraldi C, Volpato S, Cesari M, et al. Anemia, physical disability, and survival in older patients with heart failure. J Card Fail 2006; 12:533-539.
39. Kosiborod M, Curtis JP, Wang Y, et al. Anemia and outcomes in patients with heart failure: a study from the National Heart Care Project. Arch Intern Med 2005; 165:2237-2244.
40. Go AS, Yang J, Ackerson LM, et al. Hemoglobin level, chronic kidney disease, and the risks of death and hospitalization in adults with chronic heart failure: the Anemia in Chronic Heart Failure: Outcomes and Resource Utilization (ANCHOR) Study. Circulation 2006; 113:2713-2723.
41. Tang WHW, Tong W, Jain A, et al. Evaluation and long-term prognosis of new-onset, transient, and persistent anemia in ambulatory patients with chronic heart failure. J Am Coll Cardiol 2008; 51:569-576. This study shows the dynamic nature of anemia in heart failure.
42. Kosiborod M, Krumholz HM, Jones PG, et al. The relationship between anemia, change in hematocrit over time and change in health status in patients with heart failure after myocardial infarction. J Card Fail 2008; 14:27-34.
43. Jensen NM, Brandsborg M, Boesen AM, et al. Low-dose oral iron absorption test in anaemic patients with and without iron deficiency determined by bone marrow iron content. Eur J Haematol 1999; 63:103-111.
44. Joosten E, Vander Elst B, Billen J. Small-dose oral iron absorption test in anaemic and nonanaemic elderly hospitalized patients. Eur J Haematol 1997; 58:99-103.
45. Fishbane S. Safety in iron management. Am J Kidney Dis 2003; 41 (Suppl 5):18-22.
46. Chua AC, Graham RM, Trinder D, Olynyk JK. The regulation of cellular iron metabolism. Crit Rev Clin Lab Sci 2007; 44:413-459. An excellent review of the cellular biology of iron.
47. Weiss G, Meusburger E, Radacher G, et al. Effect of iron treatment on circulating cytokine levels in ESRD patients receiving recombinant human erythropoietin. Kidney Int 2003; 64:572-578.
48. Dong F, Zhang X, Culver B, et al. Dietary iron deficiency induces ventricular dilation, mitochondrial ultrastructural aberrations and cytochrome c release: involvement of nitric oxide synthase and protein tyrosine nitration. Clin Sci (Lond) 2005; 109:277-286.
49. Auerbach M, Goodnough LT, Picard D, Maniatis A. The role of intravenous iron in anemia management and transfusion avoidance. Transfusion 2008; 48:988-1000. An excellent review of intravenous iron supplementation.
50. Slotki I. Intravenous iron supplementation in the anaemia of renal and cardiac failure: a double-edged sword? Nephrol Dial Transplant 2005; 20:6-23.
51. Usmanov RI, Zueva EB, Silverberg DS, Shaked M. Intravenous iron without erythropoietin for the treatment of iron deficiency anemia in patients with moderate to severe congestive heart failure and chronic kidney insufficiency. J Nephrol 2008; 21:236-242.
52. Toblli JE, Lombrana A, Duarte P, Di Gennaro F. Intravenous iron reduces NT-pro-brain natriuretic peptide in anemic patients with chronic heart failure and renal insufficiency. J Am Coll Cardiol 2007; 50:1657-1665.
53. Okonko DO, Grzeslo A, Witkowski T, et al. Effect of intravenous iron sucrose on exercise tolerance in anemic and nonanemic patients with symptomatic chronic heart failure and iron deficiency: FERRIC-HF - a randomized, controlled, observer-blinded trial. J Am Coll Cardiol 2008; 51: 103-112.
54. Brownlie TT, Utermohlen V, Hinton PS, Haas JD. Tissue iron deficiency without anemia impairs adaptation in endurance capacity after aerobic training in previously untrained women. Am J Clin Nutr 2004; 79:437-443.
55. Beck-da-Silva L, Rohde LE, Pereira-Barretto AC, et al. Rationale and design of the IRON-HF study: a randomized trial to assess the effects of iron supplementation in heart failure patients with anemia. J Card Fail 2007; 13:14-17.
56. Palazzuoli A, Silverberg D, Iovine F, et al. Erythropoietin improves anemia exercise tolerance and renal function and reduces B-type natriuretic peptide and hospitalization in patients with heart failure and anemia. Am Heart J 2006; 152:1096.e9-1096.e15.
57. Palazzuoli A, Silverberg DS, lovine F, et al. Effects of beta-erythropoietin treatment on left ventricular remodeling, systolic function, and B-type natriuretic peptide levels in patients with the cardiorenal anemia syndrome. Am Heart J 2007; 154:645.e9-645.e15.
58. Ponikowski P, Anker SD, Szachniewicz J, et al. Effect of darbepoetin alfa on exercise tolerance in anemic patients with symptomatic chronic heart failure: a randomized, double-blind, placebo-controlled trial. J Am Coll Cardiol 2007; 49:753-762.
59. van Veldhuisen DJ, Dickstein K, Cohen-Solal A, et al. Randomized, double-blind, placebo-controlled study to evaluate the effect of two dosing regimens of darbepoetin alfa In patients with heart failure and anaemia. Eur Heart J 2007; 28:2208-2216.
60. Ghali JK, Anand IS, Abraham WT, et al. Randomized double-blind trial of darbepoetin alfa in patients with symptomatic heart failure and anemia. Circulation 2008; 117:526-535. This the largest study with darbepoietin alfa in systolic heart failure that showed a trend for improvement in outcome. Although the study failed to achieve its primary endpoint of change in exercise time, a post-hoc analysis showed a hemoglobin-associated increase in exercise time.
61. Parissis J, Kourea K, Panou F, et al. Effects of darbepoetin α on right and left ventricular systolic and diastolic function in anemic patients with chronic heart failure secondary to ischemic or idiopathic dilated cardiomyopathy. Am Heart J 2008; 155:751-757.
62. Zilberman M, Silverberg DS, Bits I, et al. Improvement of anemia with erythropoietin and intravenous iron redues sleep-related breathing disorders and improves daytime sleepiness in anemic patients with congestive heart failure. Am Heart J 2007; 154:870-876.
63. Gao E, Boucher M, Chuprun JK, et al. Darbepoeitin alfa, a long acting erythryopoietin analog, offers novel and delayed cardioprotection for the ischemic heart. Am J Physiol Heart Circ Physiol 2007; 293:60-68.
64. Asaumi Y, Kagaya Y, Takeda M, et al. Protective role of endogenous erythropoietin system in nonhematopoietic cells against pressure overload-induced left ventricular dysfunction in mice. Circulation 2007; 115:2022-2032.
65. Lipsic E, Shoemaker RG, van der Meer P, et al. Protective effects of erythropoietin in cardiac ischemia. J Am Coll Cardiol 2006; 48:2161-2167.
66. Latini R, Brines M, Fiordaliso F. Do nonhemopoietic effects of erythryopoietin play a beneficial role in heart failure? Heart Fail Rev 2008; 4:415-423. A concise summary of the nonhemapoitic effects of erythropoietin.
67. Akram K, Pearlman BA. Congestive heart failure-related anemia and a role for erythropoietin. Int J Cardiol 2007; 117:296-305.
68. Liu X, Xie W, Liu P, et al. Mechanism of the cardioprotection of rhEPO pretreatment on suppressing the inflammatory response in ischemia-reperfusion. Life Sci 2006; 78:2255-3226.
69. Liu J, Narasimban P, Song YS, et al. Epo protects SOD2-dificient mouse astrocytes from damage by oxidative stress. Glia 2006; 53:360-365.
70. Wald M, Gutnisky A, Borda E, et al. Erythropoietin modified the cardiac action of ouabain in chronically anaemic-uraemic rats. Nephron 1995; 71:190-196.
71. Porat O, Neumann D, Zamir O, et al. Erythropoietin stimulates atrial natriuretic peptide secretion from adult rat cardiac atrium. J Pharmacol Exp Ther 1996; 276:1162-1168.
72. Drueke TB, Locatelli F, Clyne N, et al. Normalization of hemoglobin level in patients with chronic kidney disease and anemia. N Engl J Med 2006; 355:2071-2084.
73. Singh AK, Szczech L, Tang KL, et al.Correction of anemia with epoetin alfa in chronic kidney disease. N Engl J Med 2006; 355:2085-2098.
74. van Veldhuisen DJ, McMurray JJ. Are erythropoietin stimulating proteins safe and efficacious in heart failure? Why we need an adequately powered randomized outcome trial. Eur J Heart Fail 2007; 9:110-112.
75. Klapholz M, Abraham WT, Ghali JK, et al. Anemiatreatment with darbepoetin alfa in patients with symptomatic heart failure. Eur Heart J (abstr) 2008; 29:505.
76. Mix TC, Brenner RM, Cooper ME, et al. Rationale: Trial to Reduce Cardiovascular Events with Aranesp Therapy (TREAT) - evolving the management of cardiovascular risk in patients with chronic kidney disease. Am Heart J 2005; 149:408-413.
77. Pfeffer MA. An ongoing study of anemia correction in chronic kidney disease. N Engl J Med 2007; 356:959.
78. Young JB, Anand IS, Diaz R, et al. Reduction of Events with Darbepoetin Alfa in Heart Failure (RED-HF) trial. J Card Fail 2006; 12 (Suppl 1):S77.